Dynamic effects of ventral hippocampal NRG3/ERBB4 signaling on nicotine withdrawal-induced responses

Miranda L Fisher1, Emily R Prantzalos1, Bernadette O'Donovan2

  • 1Department of Pharmaceutical Sciences, University of Kentucky College of Pharmacy, Lexington, KY, USA.

Neuropharmacology
|January 11, 2024
PubMed

Insights

Genetic factors influence nicotine addiction and relapse. This study shows the neuregulin 3 (NRG3)-erbB-4 (ERBB4) pathway in the ventral hippocampus is key to anxiety during nicotine withdrawal, offering new cessation therapy targets.

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Tobacco smoking is a leading cause of preventable death with low cessation success rates.
  • High relapse rates are linked to genetic factors, suggesting gene-drug interactions are crucial for novel smoking cessation therapies.
  • Neuregulin 3 (NRG3) and its receptor erbB-4 (ERBB4) single nucleotide polymorphisms (SNPs) are associated with nicotine addiction.

Purpose of the Study:

  • To investigate the neuronal mechanisms and circuit-specific effects of NRG3-ERBB4 signaling in the ventral hippocampus (VH) during nicotine use and withdrawal.
  • To examine the role of NRG3-ERBB4 signaling in anxiety-related behaviors during nicotine withdrawal in male and female mice.

Main Methods:

  • Genetic, biochemical, and functional approaches were used.
  • Examined anxiety-like behaviors and synaptic expression of NRG3 and ERBB4 in the VH of mice.
  • Investigated alterations in GABAergic transmission and network activity in the ventral CA1 area.

Main Results:

  • Nicotine withdrawal (WD) altered synaptic expression of VH NRG3 and ERBB4.
  • Genetic disruption of VH ErbB4 eliminated anxiety-like behaviors during 24-hour WD.
  • Attenuated GABAergic transmission and altered Ca2+-dependent network activity were observed in VH ErbB4 knock-down mice during WD.

Conclusions:

  • The NRG3-ERBB4 signaling pathway in the ventral hippocampus contributes to anxiety-related behaviors during nicotine withdrawal.
  • Findings highlight the potential of targeting the NRG3-ERBB4 pathway for developing novel smoking cessation therapies.